An ATM inhibitor can be used in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

An ATM inhibitor can be used in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

The invention provides a pharmaceutical composition and methods for the treatment of a respiratory disease that results from a viral infection. The pharmaceutical composition can include a peptide that interferes with the Src family kinase-Androgen receptor interaction (i.e., an “SA inhibitor”). The composition can also include Niacin or a Niacin derivative and/or a DNase I or fragment or derivative. The pharmaceutical composition can prevent the development of Acute Respiratory Distress Syndrome (ARDS) associated with Corona vims infection and allow the host adaptive immune response to overcome the infection.

The invention provides a pharmaceutical composition and methods for the treatment of a respiratory disease that results from a viral infection. The pharmaceutical composition can include a peptide that interferes with the Src family kinase-Androgen receptor interaction (i.e., an “SA inhibitor”). The composition can also include Niacin or a Niacin derivative and/or a DNase I or fragment or derivative. The pharmaceutical composition can prevent the development of Acute Respiratory Distress Syndrome (ARDS) associated with Corona vims infection and allow the host adaptive immune response to overcome the infection.

The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relates to a codrug comprising a residue of an antiviral agent covalently bonded via a labile bond to a residue of a compound of Formula (I) or Formula (II). The present disclosure further relates to a method of administering an antiviral agent and a Formula I/II compound, a pharmaceutical composition, or a codrug to treat coronavirus infection and/or associated inflammation.

The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relates to a codrug comprising a residue of an antiviral agent covalently bonded via a labile bond to a residue of a compound of Formula (I) or Formula (II). The present disclosure further relates to a method of administering an antiviral agent and a Formula I/II compound, a pharmaceutical composition, or a codrug to treat coronavirus infection and/or associated inflammation.

The invention includes methods, kits, and pharmaceutical compositions for enhancing liver regeneration in a mammal in need thereof, comprising administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity. The methods may include administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity and a sirtuin 1 (Sirt1) agonist. The agent that increases NAD activity may be a NAD precursor. The NAD precursor may include one or more of tryptophan, nicotinic acid, nicotinic acid riboside, nicotinamide riboside (NR), nicotinamide, NADP, and NAD itself, and a pharmaceutically acceptable salt thereof.

The invention includes methods, kits, and pharmaceutical compositions for enhancing liver regeneration in a mammal in need thereof, comprising administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity. The methods may include administering a therapeutically effective amount of an agent that increases nicotinamide adenine dinucleotide (NAD) activity and a sirtuin 1 (Sirt1) agonist. The agent that increases NAD activity may be a NAD precursor. The NAD precursor may include one or more of tryptophan, nicotinic acid, nicotinic acid riboside, nicotinamide riboside (NR), nicotinamide, NADP, and NAD itself, and a pharmaceutically acceptable salt thereof.

Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.

Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.